3-pentadecacatechol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3-pentadecylcatechol : Catechol substituted at position 3 with a pentadecyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 68118 |
| CHEMBL ID | 8087 |
| CHEBI ID | 59111 |
| SCHEMBL ID | 554986 |
| MeSH ID | M0046751 |
| Synonym |
|---|
| 1,2-benzenediol, 3-pentadecyl- |
| usaf uctl-1803 |
| 3-pentadecacatechol |
| brn 1885390 |
| nsc 403211 |
| 3-pdc |
| pyrocatechol, 3-pentadecyl- |
| 3-n-pentadecylpyrocatechol |
| hydrourushiol |
| tetrahydrourushiol |
| wln: qr bq c15 |
| 3-pentadecylpyrocatechol |
| 3-n-pentadecylcatechol |
| hydroureshiol |
| 3-pentadecylcatechol |
| dihydrorhengol |
| 1, 3-pentadecyl- |
| nsc-403211 |
| 492-89-7 |
| nsc403211 |
| CHEMBL8087 , |
| chebi:59111 , |
| 3-pentadecylbenzene-1,2-diol |
| 51m8x101ml , |
| unii-51m8x101ml |
| 4-06-00-06109 (beilstein handbook reference) |
| 3-pentadecyl-benzene-1,2-diol |
| EPITOPE ID:122677 |
| SCHEMBL554986 |
| (15:0)-urushiol [mi] |
| urushiol i |
| urushiol, (15:0)- |
| 3-pentadecyl-1,2-benzenediol |
| 3-pentadecylcatechol [mi] |
| urushiol i [mi] |
| (15:0)-urushiol |
| 6f8 , |
| 3-(pentadecyl)-catechol |
| LMPK15020001 |
| DTXSID70197714 |
| pentadecylcatechol |
| ncgc00386000-01!3-pentadecylbenzene-1,2-diol |
| urushiol i (c15:0) |
| Q27104847 |
| bdbm50469662 |
| AKOS040734849 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " High doses produced a greater degree of hyposensitization regardless of the dosage schedule used." | ( Immunologic studies of poisonous Anacardiaceae: oral desensitization to poison ivy and oak urushiols in guinea pigs. ElSohly, MA; Murphy, JC; Watson, ES, 1983) | 0.27 |
| Role | Description |
|---|---|
| allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| catechols | Any compound containing an o-diphenol component. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID112718 | Increase in ear thickness was determined in mice after 48 hr of application of compound at a concentration of 1.56 mmol to right ear | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Perfluorinated analogues of poison ivy allergens. Synthesis and skin tolerogenic activity in mice. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 16 (76.19) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (9.52%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (90.48%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||